Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Satellos Bioscience Inc.

Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos to Participate in Oppenheimer Movers in Rare Disease Summit
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Appoints Stephanie Brown to Board of Directors
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Reports Q3 2024 Financial Results and Provides Clinical Update
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos to Participate in November 2024 Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Participation in September 2024 Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Q2 2024 Financial Results and Updated Canine Data
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy (“DMD”)
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Bioscience Announces Q1 2024 Financial Results and Operational Highlights
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos to Present at Upcoming Virtual Investor Conferences in March and April
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Recognized as a Top 50 TSX Venture Exchange Company
From Satellos Bioscience Inc.
Via Business Wire
Tickers TSX:MSCL
Satellos Announces Upcoming Presentations at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos to Commence Trading on the Toronto Stock Exchange
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX-V:MSCL
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.